Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SK Bio Begins New Coronavirus Vaccine Development Using Versatile Platform

Executive Summary

Korean vaccine specialist SK Bioscience moves to develop versatile platform technology to deal with outbreaks of infectious diseases such as the new coronavirus, as the number of infections in the country surges.

You may also be interested in...



SK Bioscience Readies $1.3bn IPO Amid Rosy Vaccine Outlook

Vaccine specialist SK Bioscience is set to launch potentially South Korea’s biggest biopharma IPO next month on the back of a growing premium vaccine business, new opportunities in COVID-19 vaccines and its contract manufacturing operations.

Capacity, Expertise Drive Korea's Emergence As COVID-19-Related Manufacturing Base

A series of major COVID-19-related manufacturing deals reached by South Korean firms indicate the country could emerge as a major base for the production of drugs and vaccines.

Korean Pharma Accelerates Coronavirus-Related R&D, Calls For More Support

As South Korean companies jump into the development of vaccines and drugs for the coronavirus, they also call for stronger government support and increased collaboration between the state and private sectors.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141718

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel